|Bid||129.65 x 900|
|Ask||129.67 x 900|
|Day's Range||129.36 - 130.47|
|52 Week Range||118.62 - 148.32|
|PE Ratio (TTM)||257.59|
|Earnings Date||Oct 16, 2018|
|Forward Dividend & Yield||3.60 (2.74%)|
|1y Target Est||143.35|
Alan Valdes of Silverbear Capital joins Yahoo Finance's Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves. Here's the performance of select trending stocks as of 3:00 pm ET: CGC(HB) Canopy Growth 4.03% CVS CVS Health Corp 3.69% GEVO(HB) Gevo Inc 2.58% BB(HB) BlackBerry Ltd 2.44% FIT Fitbit Inc 2.25% ACBFF(HB) Aurora Cannabis Inc 2.13% ARWR(0) Arrowhead Pharma Inc 1.46% LRCX Lam Research 1.19% PFE Pfizer Inc 0.95% GOOGL Alphabet Inc Cl A 0.94% NVDA Nvidia Corp 0.92% AMZN Amazon.com Inc 0.89% SIRI Sirius XM Hldgs Inc 0.80% GOOG Alphabet Inc Cl C Cap Stock 0.88% BILI(HB) Bilibili Inc ADS 0.79% C Citigrp Inc 0.70% BAC Bank of America Corporation 0.67% FB Facebook Inc 0.61% AMAT Applied Materials 0.42% CRM salesforce.com Inc 0.43% JCP(HB) Penney (J.C.) 0.42% JPM JPMorgan Chase & Co 0.37% WFC Wells Fargo 0.34% HD Home Depot Inc 0.31% VZ Verizon Communications 0.29% T AT&T Inc 0.29% SHOP Shopify Inc 0.29% PBR Petroleo Brasileiro S.A. ADS 0.16% HMNY(HB,F) Helios and Matheson Analytics 0.14% MSFT Microsoft Corp 0.14% ADBE Adobe Systems 0.12% AVGO Broadcom Inc 0.06% PYPL PayPal Hldgs Inc 0.08% AAPL Apple Inc 0.01% QQQ Invesco QQQ Trust Series 1 0.02% KMI Kinder Morgan Inc -0.03% CSCO Cisco Systems -0.02% CELG Celgene Corp -0.02% ORCL Oracle Corp -0.08% ABBV AbbVie Inc -0.11% V Visa Inc -0.06% SPY SPDR S&P 500 ETF -0.14% QCOM Qualcomm Inc -0.15% INTC Intel Corp -0.17% MU Micron Tech -0.14% F Ford Motor -0.20% TVIX(HB) VS 2X VIX Short Term -0.19% NKTR(0) Nektar Therapeutics -0.27% JNJ Johnson & Johnson -0.30% PG Procter & Gamble Cc -0.35% WMT Wal-Mart Stores -0.37% BP BP P.L.C. ADS -0.38% NKE Nike Inc Cl B -0.41% IBM Intl Business Machines Corp -0.43% SQ Square Inc -0.42% KO Coca-Cola Co -0.43% VXX iPath S&P 500 VIX Short-Term -0.42% AMD Advanced Micro Devices Inc -0.49% UVXY ProShs Ultra VIX Short-Term -0.25% NFLX Netflix Inc -0.47% SDRL(HB) Seadrill Limited -0.50% BIDU Baidu Inc -0.62% BA Boeing Co -0.64% CVX Chevron Corporation -0.80% XOM Exxon Mobil -0.81% JD JD.com Inc -0.88% BABA Alibaba Group Holding Ltd -0.92% GE General Electric Co -0.99% GILD Gilead Sciences -1.00% CMCSA(HB) Comcast Cl A -1.09% SRPT Sarepta Therapeutics Inc -1.12% SBUX Starbucks Corp -1.23% TSLA(HB) Tesla Inc -1.17% CHK Chesapeake Energy Corp -1.28% WBA Walgreen Boots Alliance Inc -1.29% TWTR Twitter Inc -1.32% SOGO(HB) Sogou Inc -1.40% CAT Caterpillar Inc -1.40% MO Altria Grp -1.58% TEVA Teva Pharm Indus ADR -1.70% DBX Dropbox Inc -1.82% IQ IQIYI Inc ADS -2.01% RAD Rite Aid -2.33% DIS Disney (Walt) Co -2.06% ROKU Roku Inc Cl A -2.24% HUYA(HB) HUYA Inc -2.62% GERN(HB) Geron Corp -2.44% X U.S. Steel Corporation -2.59% SNAP(HB) Snap Inc -6.02% TRXC(HB) TransEnterix Inc -7.98%
Erika Hayes James became the first African-American woman appointed dean of a top-25 business school when she was tapped for the role at the John H. Harland Dean of Goizueta Business School in 2014.
One popular form of dividend investing involves a group of stocks called dividend aristocrats. Standards of what makes up a dividend aristocrat vary. Of the thousands of stocks that trade on American exchanges, only 53 stocks currently hold dividend aristocrat status.
In this daily bar chart of JNJ, below, we can see that JNJ has been testing the declining 200-day moving average line. The daily On-Balance-Volume (OBV) line has been going up since early June and it is close to making a new high above the April peak. A rising OBV line is a sign that buyers of a stock are being more aggressive.
Shire's (SHPG) Japanese partner Shionogi & Co., Ltd submits a new drug application for Intuniv in Japan for the treatment of attention deficit hyperactivity disorder (ADHD) in adults.
The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers
Like many tech stocks, Cisco Systems (NASDAQ:CSCO) has declined in recent days. Now that the shares are roughly 7.5% off the highs reached in May, is it time to pull the trigger and buy Cisco? For those interested in the name, here are three catalysts that can push Cisco higher.
Novo Nordisk (NVO) reports strong Q2 results. J&J (JNJ) seeks approval for new dosing regimen of multiple myeloma drug. Allergan (AGN) exercises option to buy Editas' lead ocular candidate.
The United States on Wednesday announced it would impose fresh sanctions on Russia after Washington determined Moscow had used a nerve agent against a former Russian double agent, Sergei Skripal, and his daughter, Yulia, in Britain. Russia on Thursday condemned the new round of sanctions as illegal and said it had begun working on retaliatory measures.
Generic drugmakers are being crushed by the very forces that the Trump administration is counting on to drive down prescription costs. While policy makers are betting that opening the market to a deluge of new medicines and reforming the drug supply chain will help contain rising prices, many widely used copycat medications are already seeing their prices fall at such a rapid rate that their makers are struggling to keep their heads above water. As a result, companies including Mylan NV and Perrigo Co. are being forced to consider shakeups.
Pfizer (PFE) is focused on discovering, developing, and manufacturing healthcare products. Pfizer’s portfolio includes medicines, vaccines, and consumer healthcare products. Pfizer’s top line rose ~4% to $13.5 billion in the second quarter of 2018 compared to $12.9 billion in the second quarter of 2017.
Mr. DelOrefice has been with Johnson & Johnson for 19 years and has most recently served as the CFO of the North America Hospital Medical Devices (MD) Business. Mr. DelOrefice holds a Bachelor of Science and MBA from Villanova University, and received his CPA certification from the Commonwealth of PA.
Pfizer’s (PFE) portfolio also includes a few products that are losing market share due to competition from other products in the market. These products include Enbrel (outside the United States and Canada), Sutent, Xalkori, BeneFix, Premarin Family, Medrol, Celebrex, Lyrica, and Viagra.
NEW BRUNSWICK, N.J. , Aug. 7, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 2018 Wells Fargo 13 th Annual Healthcare Conference on Thursday, Sept. 6 th , at The Westin Boston ...
NEW BRUNSWICK, N.J. , Aug. 7, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Barclays Global Consumer Staples Conference on Thursday, Sept. 6 th , at the InterContinental, Boston ...
Pfizer (PFE) reports its revenue into two business segments: Innovative Health and Essential Health. As we discussed in the previous article, Pfizer reported a YoY (year-over-year) rise of 4% in its top line to $13.5 billion in the second quarter compared to $12.9 million during the second quarter of 2017. This outperformance was driven by a 2% favorable foreign exchange impact and a 2% rise in operating revenue in the second quarter.
U.S. President Donald Trump will dine with some of corporate America's top business leaders at his private club on Tuesday, seeking their thoughts on the nation's economy as voters begin heading to the polls ahead of November's midterm election. Trump is hosting the chief executives for dinner at his golf resort in Bedminster, New Jersey. Expected attendees include the heads of Fiat Chrysler Automobiles NV, Boeing Co , FedEx Corp, and Honeywell International Inc , White House Deputy Press Secretary Lindsay Walters said.
A few months ago, Benzinga visited several countries in South America and subsequently published an article explaining why cannabis investors’ interest in the region, especially in Colombia, was about to spike. In the weeks that followed, numerous U.S. and Canada-based marijuana companies announced deals to enter the Colombian market, with Aphria Inc (OTC: APHQF) spending almost $200 million and Canopy Growth Corp (NYSE: CGC) dropping close to $100 million. On Monday, Benzinga learned about a new multimillion-dollar deal in Colombia: Avicanna Inc., the first and only cannabidiol company to be accepted into Johnson & Johnson (NYSE: JNJ)’s JLABS @ Toronto, and El Grupo Daabon, the largest organic agriculture company in South America, in operation for more than 100 years, have entered into joint venture to cultivate and process cannabis.